Issue 70

Psychedelic healthcare and PTSD

It is estimated 15 million people suffer from PTSD each year, with wide-reaching socioeconomic consequences.

Many of those afflicted are ex-armed forces and emergency services personnel, with SSRIs typically the frontline treatment.

However, many patients do not respond to these medications and, as a result, go untreated – developing comorbidities such as major depressive disorder, substance abuse and suicidality.

When conventional treatments fail, Heroic Hearts UK connects British veterans with PTSD to psychedelic-assisted therapy services around the world.

CEO Keith Abraham will be joining industry leaders at the PSYCH Symposium on Wednesday 11 May, to share insights from the organisation’s extraordinary work.

STUDY FINDS FEW DIFFERENCES IN EFFECTS OF PSILOCYBIN AND LSD

This indicates the psychedelic medicines may be interchangeable in the future, which broadens their potential application.

THE REGULATORY LANDSCAPE OF PSYCHEDELIC HEALTHCARE IN EUROPE IS EVOLVING

PharmaTimes provides an overview of the frameworks governing European research and innovation in psychedelic medicine.

BUSINESS AND INVESTMENT

COMPASS, Novamind, Braxia and Red Light Holland report financial results.

What should investors know about clinical trials?

Filament Health and ATMA Journey Centers enter licensing agreement.

Dr. Bronner’s offers employees ketamine-assisted therapy.

PSYCH Symposium: London 2022

PSYCH Symposium enables industry leaders to connect and collaborate to expedite access to psychedelic healthcare across Europe.

The conference will bring together leading figures from policy, science and business.

Speakers include:

Carol Routledge – Chief Medical and Scientific Officer, Small Pharma
Crispin Blunt MP – Chair, Conservative Drug Policy Reform Group
Natalie Ginsberg – Global Impact Officer, MAPS

Secure your ticket today to connect with industry influencers, learn from the sector’s thought leaders and contribute to the future of psychedelics as medicine in Europe.

For speaking and partnership opportunities, please visit the website.

Ticket registration

SCIENCE AND RESEARCH

More people are microdosing, but does it work?

Could psychedelics revolutionise how we treat depression?

Core One Labs claims to have reduced the cost of psilocybin synthesis.

REGULATION AND LEGISLATION

How will Oregon teach and train psilocybin healers?

Canadian health practitioners challenge access to psilocybin.

Second Hawaii committee approves psilocybin bill.

In Oregon, psychedelics regulators confront conflicts of interest.